Publications

5900 Results

A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results

Authors
Chae YK
Journal / Conference
Journal of Gynecologic Oncology. 2026 Mar 25; e92. DOI: 10.3802/jgo.2026.37.e92. Epub ahead of print
Year
2026
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID41995270
Study Number(s)
S1609

Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609)

Authors
Swiecicki PL;Othus M;Patel SP;Chae YK;Kurzrock R
Journal / Conference
Cancer. 2026 Apr 1; e70374. DOI: 10.1002/cncr.70374.
Year
2026
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID41892875
Study Number(s)
S1609

Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1

Authors
Campbell KM;Chen DG;Bustami ZE;Al Deen NN;Medina E;Gonzalez CR;Maxey J;Thompson MA;Samorodnitsky S;Kuklinski LF;Perez Garcilazo I;Baselga-Carretero I;Vega-Crespo A;Chen JM;Elumalai R;Visitacion M;Schiemann R;Padron L;Chang C;Zelin AE;Chelluri SS;Boffo S;Kendra KL;Chmielowski B;Truong TG;Khushalani NI;Collichio F;Ikeguchi AP;Victor AI;Margolin KA;Johnson DB;Chen Y;Sosman JA;Patel SP;Hu-Lieskovan S;Moon J;Wells DK;Bellasea S;Vanderwalde AM;Wu MC;Scumpia PO;Ribas A
Journal / Conference
Cancer Discovery. 2026 Apr 21; . DOI: 10.1158/2159-8290.CD-25-1745.
Year
2026
Research Committee(s)
Melanoma
Study Number(s)
S1616

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826

Authors
Castellino SM;Li H;Herrera AF;LeBlanc ML;Parsons SK;Unger JM;Punnett A;Hodgson D;Keller FG;Drachtman RA;Lamble A;Forlenza CJ;Doan A;Rutherford SC;Evens AM;Little RF;Smith MA;Hoppe BS;Song JY;Smith SM;Friedberg JW;Kelly KM
Journal / Conference
Journal of Clinical Oncology. 2026 Jan 9; JCO2500203. DOI: 10.1200/JCO-25-00203.
Year
2026
Research Committee(s)
Lymphoma
PMID
PMID41512237
PMC
13192332
Study Number(s)
S1826

Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model

Authors
Vertosick EA;Goodman P;Tangen CM;Till C;Thompson IM;Lucia MS;Eastham J;Lilja H;Vickers AJ
Journal / Conference
European Urology Focus. 2026 Mar 20; S2405-4569(26)00038-6. DOI: 10.1016/j.euf.2026.03.005. Online ahead of print
Year
2026
Research Committee(s)
Cancer Control
PMID
PMID41864782
Study Number(s)
SWOG-9217

Indian Hedgehog expression and association with cetuximab benefit in metastatic colorectal cancer (mCRC): Evidence from CALGB (Alliance)/SWOG 80405.

Authors
Bartolini M;Yang Y;Millstein J;Ou FS;Soni S;Battaglin F;Mittal P;Algaze S;Shah UH;Torres-Gonzalez L;Zhang W;Venook AP;Innocenti F;Puccini A;Lenz HJ
Journal / Conference
ASCO GI Cancers Symposium (January 8-10, 2026, San Francisco, CA); Poster; Abstract #198
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Neuroligin family genes expression associated with first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance).

Authors
Zhang W;Shah UH;Yang Y;Millstein J;Soni S;Algaze S;Mittal P;Torres-Gonzalez L;Battaglin F;Mulkerin DL;Ou FS;Venook AP;Innocenti F;Lenz HJ
Journal / Conference
ASCO GI Cancers Symposium (January 8-10, 2026, San Francisco, CA); Poster; Abstract #179
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Colorectal cancer metastatic dMMR Immuno-Therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC): NRG-GI004/SWOG-S1610.

Authors
Lima CMSPR;Yothers G;George TJ;Hochster HS;Sanoff HK;Cohen DJ;Guthrie KA;Jacobs SA;Saeed A;Kopetz S;Colangelo LH;Freeman T;Cole SW;Zuckerman DS;Hong TS;Henry NL;Ganz PA;Blanke CD;Wolmark N;Overman MJ
Journal / Conference
ASCO Gastrointestinal Cancers Symposium (January 8-10, 2026); Oral Abstract #14
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/NRG-GI004

No effect of the time-of-day infusion of adjuvant pembrolizumab in the outcomes of patients with resectable melanoma in the NCI/SWOG trial S1404.

Authors
Othus M;Truong TG;Sharon E;Kendra K;Grossman K;Buchbinder E;Khushalani N;Eroglu Z;Chandra S;Doolittle GC;Kirkwood JM;Johnson D;Taylor M;Sondak VK;Ribas A;Patel SP
Journal / Conference
AACR Immuno-Oncology Conference (February 18-21, 2026, Los Angeles, CA); Oral LB-B005
Year
2026
Research Committee(s)
Melanoma
Study Number(s)
S1404

Inflammatory spatial niches distinguished by antigen presentation and interferon response programs explain the high immune response rate of desmoplastic melanoma: Comparison of biopsies from SWOG S1512 and S1616.

Authors
Chen DG;Truong A;Al Deen NN;Gonzalez CR;Baselga-Carretero I;Chen JM;Kendra KL;Eroglu Z;Hu-Lieskovan S;Vanderwalde AM;Wada DA;Plaza JA;Wu MC;Scumpia PO;Ribas A;Campbell KM
Journal / Conference
AACR Immuno-Oncology Conference (February 18-21, 2026, Los Angeles, CA); Abstract B038
Year
2026
Research Committee(s)
Melanoma
Study Number(s)
S1512, S1616